Apellis therapy outperforms Alexion's Soliris in a clinical trial comparison

Apellis therapy outperforms Alexion's Soliris in a clinical trial comparison

STAT Plus: Apellis Pharmaceuticals’ drug candidate outperforms Alexion’s Soliris in a clinical trial comparing the two

By KATE SHERIDAN

ALEX HOGAN/STAT; ADOBE

In a late-stage clinical trial, Apellis' drug candidate for a rare, life-threatening blood disorder helped patients more than Alexion's Soliris.

READ MORE